The Toronto-based molecular diagnostics maker also plans to enter applied markets in the near term, and ultimately point-of-care infectious disease testing.
The firm said it anticipates using the financing for further commercialization and expansion of its infectious disease testing vertical, among other activities.
Discover magazine reports that animal dissections might dissuade students from science careers, but that a firm has developed synthetic frogs for dissections.
